Ngo-Okthoba 19, 2016, umuthi omusha i-Olaratumab wadlulisa imvume esheshayo ye-US FDA futhi ingahlanganiswa ne-doxorubicin ukwelapha izinhlobo ezithile ze-sarcoma (STS) yabantu abadala.
okubalulekile; ukugoqa amagama: i-break-word! okubalulekile; uhlaka: akukho 0px! okubalulekile; NgoMeyi kulo nyaka, i-FDA yanikeza i-Olaratumab imfanelo yokubuyekeza kuqala. I-Olaratumab ekuqaleni yayiklanyelwe ukuvimba indlela yokusayina ye-PDGFRα kumaseli wesimila kanye nemvelo encane. Ephendula le ndlela yesenzo, i-Olaratumab iphinde yaphasisa imvume ye-FDA" yezidakamizwa ", "Ithrekhi Esheshayo" kanye "Nezidakamizwa Zezintandane".
okubalulekile; ukugoqa amagama: i-break-word! okubalulekile; uhlaka: akukho 0px! okubalulekile; "> I-Olaratumab iyi-antibody ye-monoclonal ye-IgG1 esuselwe kumuntu enobudlelwano obuqondiswe okuphezulu kwe-α (PDGFRα) esuselwa ku-platelet-derived growth factor receptor. Olunye ucwaningo luthole ukuthi i-PDGFRα itholakala kuma-tumors ahlukahlukene Expression, futhi ukwenziwa kusebenze okungavamile kwalesi samukeli kunobudlelwano obuthile namathumba. Ucwaningo lwe-Preclinical lukholelwa ukuthi i-PDGFRα ingase ikhulise ukwanda kwe-tumor kanye namandla e-metastatic.
portant; ukugoqa igama: phula-gama! imokubalulekile; uhlaka: akukho 0px! okubalulekile; "> I-Olaratumab umuthi wokuqala wokwelapha we-STS ngemva kokugunyazwa kwe-indosine kanye ne-radiotherapy eminyakeni engaphezu kwengu-40 edlule. Kulezi ziguli, indlela yokwelapha esetshenziswa kakhulu kwakuyi-doxorubicin noma Hlanganisa neminye imithi.
okubalulekile; ukugoqa amagama: i-break-word! okubalulekile; uhlaka: akukho 0px! okubalulekile; "> Ukuhlolwa komtholampilo kweziguli eziyi-133 ezine-STS ye-metastatic equkethe izinhlobo zezicubu ezihlukene ezingama-25 kuhlole ukusebenza nokuphepha kwe-Olaratumab. Imiphumela yocwaningo ibonise ukuthi i-Olaratumab ihlanganiswe nokwelashwa kwe-adriamycin ye-agent eyodwa Ukusinda kweziguli eqenjini lokwelapha i-adriamycin kwathuthukiswa kakhulu, nokusinda okuphelele okuphakathi kwezinyanga ezingu-14.7 vs 26.5; ukusinda okumaphakathi kwezinyanga ezi-4.4 vs 8.2; kanye namazinga okuhlehla kwesimila angu-7.5% vs 18.2%, ngokulandelana.
okubalulekile; ukugoqa amagama: i-break-word! okubalulekile; uhlaka: akukho 0px! okubalulekile; "> Ukwelashwa kwe-Olaratumab kunobungozi bezehlakalo ezimbi kakhulu, okuhlanganisa ukusabela okuhlobene nokumnika kanye nokulimala kombungu-fetus. Ukusabela okuhlobene nokumnika kufaka phakathi i-hypotension, imfiva, ukugodola, nokuqubuka. Imiphumela evame kakhulu yokwelashwa isicanucanu, ukukhathala, kanye neGranulocytopenia engathathi hlangothi, ubuhlungu bemisipha namathambo, i-mucositis, ukuqothuka kwezinwele, ukuhlanza, isifo sohudo, ukungakuthandi ukudla, ubuhlungu besisu, i-neuropathy, nekhanda elibuhlungu.
